跳至主要内容
临床试验/IRCT2016121031288N2
IRCT2016121031288N2已完成3 期

Efficacy and safety assessment of Januluma cream for treatment of moderate to severe melasma . A single arm, phase II clinical trial

Jarfandishan-e Navid-e Salamat (Janus) knowledge-based company0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 50 years(—)
性别
All

入选标准

  • Inclusion : Case of moderate to severe melasma (MGSC>2); age range 18-50 (men or women); signed informed consent voluntarily and knowingly Exclusion :pregnancy or lactation? use of systemic corticosteroid, isotretinoin within 28 days prior to the study; use any light sensitive drug within 3 months prior to the study? Active skin disease at test area: rosacea, atrophy, acne, eczema; Use of topical lightening products like AHA ,BHA and retinoid component within 21 days prior to the study; Documented allergies to components of Januluma cream? Use of contraceptive or any hormonal drugs? History of laser treatment or dermabrasion or deep facial peels within the past 3 months

排除标准

  • 未提供

研究者

发起方
Jarfandishan-e Navid-e Salamat (Janus) knowledge-based company

相似试验

Effect of whitening cream on melasma | 临床试验